Rubric Capital Management LP's Form 4 filing
TherapeuticsMD, Inc. (TXMD) · filed Dec 12, 2022
- Accession no.
- 0001104659-22-126117
- Filed
- Dec 12, 2022, 11:14 AM ET
- Trade date
- Dec 9, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $90.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rubric Capital Management LPCIK 0001687509 | 10% Owner |
| Rosen David EfraimCIK 0001898677 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock, par value $0.001 per share ("Common Stock") | PPurchaseAcquired | +14,825 | $6.09F1 | +$90,284.25 | 1,757,191 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.15, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.